docetaxel (Taxotere, Docefrez)
Jump to navigation
Jump to search
Introduction
Tradename: Taxotere.
Indications
- locally advanced or metastatic breast cancer with progression or relapse after anthracycline therapy
- ovarian cancer
- gastric cancer[3]
- small cell carcinoma
- non small cell carcinoma
- Ewing sarcoma
- osteosarcoma
- esophageal cancer
- bladder cancer
- androgen-independent prostate cancer[3]
Contraindications
Caution:
- severe hypersensitivity in 25% of patients not receiving premedication docetaxel administration
Dosage
- premedication with dexamethasone 16 mg PO QD for 3 days starting 1 day prior to administration of docetaxel
Injection:
- 10 mg/mL (2mL, 8mL, 16mL vials)
- 20 mg/mL (1mL, 4mL vials)
- 40 mg/mL (0.5 mL, 2 mL) (contains ethanol)[4]
Pharmacokinetics
- extensive extravascular distribution
- protein binding 94%, largely albumin, alpha-1 acid glycoprotein & lipoproteins
- metabolism by cyt P450 3A
- triphasic elimination: 1/2lives 4 min, 36 min & 11 hours
elimination via liver
1/2life = 11 hours terminal-phase
Adverse effects
- common (> 10%)
- fever, alopecia (nearly all patients), nausea/vomiting, diarrhea, stomatitis, neutropenia (dose-limiting), leukopenia, thrombocytopenia, anemia, myalgia
- not common (1-10%)
- fluid retention syndrome:
- pleural effusion, edema, ascites
- incidence & severity increase markedly at cumulative doses of > 400 mg/m2
- dyspnea at rest
- cardiac tamponade (due to ascites)
- fluid retention syndrome:
- uncommon (< 1%)
- hypersensitivity reactions
- other
- symptoms of alcohol intoxication (contains ethanol)[4]
- hand & foot syndrome[5]
- cumulative dose may be associated with persisitent peripheral neuropathy in breast cancer survivors[6]
Drug interactions
- possibly increased toxicity with:
More general terms
Component of
References
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529
- ↑ 3.0 3.1 3.2 Deprecated Reference
- ↑ 4.0 4.1 4.2 FDA Safety Announcement: June 20, 2014 FDA Drug Safety Communication: FDA warns that cancer drug docetaxel may cause symptoms of alcohol intoxication after treatment. http://www.fda.gov/Drugs/DrugSafety/ucm401752.htm
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 6.0 6.1 Davenport L Neuropathy After Breast Cancer Chemo Can Last for Years. Medscape - Sep 01, 2017. http://www.medscape.com/viewarticle/885106
Bandos H, Melnikow J, Rivera DR et al Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. JNCI: Vol 110, Issue 2, 1 Feb 2018; Online Aug 24, 2017 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28954297 https://academic.oup.com/jnci/article-abstract/110/2/djx162/4093779/Long-term-Peripheral-Neuropathy-in-Breast-Cancer - ↑ 7.0 7.1 Medscape: docetaxel https://reference.medscape.com/drug/taxotere-docetaxel-342192
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=148123
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64780
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=148124
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=657391
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3143
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=363540